CONNECT WITH US
Tech

Tech

Woman Died After ChatGPT Advised Her to Stop Taking Medication, Lawsuit Alleges

CNET - Tech logo

Published on

Add as a preferred source on Google
Woman Died After ChatGPT Advised Her to Stop Taking Medication, Lawsuit Alleges

A 31-year-old Seattle woman turned to ChatGPT-4o when she became concerned about side effects from her medication.

Seeking health answers online is an everyday habit for many, but it comes with risks. In February, after going two days without hearing from their 31-year-old daughter, a Seattle woman named Bowen Wan, her parents in China asked a local friend to check on her. With the family watching over a live video call, the friend entered the apartment and found Wan deceased in her bed. Her death was later ruled the result of sudden unexpected death from epilepsy.

Now, her family is claiming that OpenAI is responsible for her death after the company’s chatbot ChatGPT-4o allegedly “coached Wan off the anti-seizure medication (lamotrigine) that had kept her alive for years,” according to a lawsuit (PDF) brought by her parents.

(Disclosure: Ziff Davis, CNET’s parent company, in 2025 filed a lawsuit against OpenAI, alleging it infringed Ziff Davis copyrights in training and operating its AI systems.)

The lawsuit alleges that after Wan expressed concerns regarding medication side effects, the chatbot helped create a plan to taper her off of it, something a doctor did not recommend.

It further alleges that at one point, the chatbot directed her not to discuss the medical plan with her doctor.

“Do not mention Lam reduction plan,” the chatbot told her ahead of an appointment, the suit says.

Throughout Wan’s chatbot conversations, the date when she would be fully off lamotrigine kept moving up, with a response on Feb.


Source link
Related Topics:Tech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.